Can I Take Zinc With Vyvanse?

Why Zinc and Vyvanse Come Up Together

Zinc is one of the most commonly discussed mineral supplements among people taking Vyvanse (lisdexamfetamine) for ADHD or binge eating disorder. The question is reasonable: zinc participates in over 300 enzymatic reactions, including neurotransmitter synthesis and dopamine regulation, both of which sit at the center of how stimulant medications work.

The Dopamine Connection

Zinc acts as a modulator at the dopamine transporter (DAT), the same protein that amphetamine-class drugs target. A 2005 study published in Behavioral and Brain Functions demonstrated that zinc concentrations influence DAT binding kinetics in vitro 1. This means zinc and lisdexamfetamine share a pharmacodynamic neighborhood, even though they arrive there by entirely different routes.

Why Clinicians Pay Attention

Several cross-sectional studies have found that children with ADHD tend to have lower serum zinc levels than neurotypical controls. A meta-analysis by Kiddie et al. (2010) pooling 2,104 participants found a statistically significant association between low zinc status and ADHD symptom severity 2. That association does not prove causation, but it has motivated a growing body of intervention research.

How the Interaction Works: Pharmacokinetics vs. Pharmacodynamics

Understanding whether zinc interferes with Vyvanse requires separating two distinct questions. Does zinc change how Vyvanse is absorbed or metabolized (pharmacokinetic)? And does zinc change the downstream effects of Vyvanse on the brain (pharmacodynamic)?

Pharmacokinetic Considerations

Vyvanse is a prodrug. The lisdexamfetamine molecule itself is pharmacologically inactive until red blood cell enzymes cleave the lysine amino acid, releasing active d-amphetamine 3. This enzymatic conversion is not zinc-dependent, and zinc does not inhibit or accelerate it.

Where zinc could have a minor pharmacokinetic effect is at the absorption stage. Divalent cations (zinc, magnesium, calcium, iron) can form chelation complexes with certain drugs in the gastrointestinal tract, reducing bioavailability. This is well-documented for tetracycline antibiotics and quinolones. For amphetamine-class compounds, the chelation risk is low, but not zero. The practical solution is simple: separate dosing by 2 hours.

Pharmacodynamic Overlap

The more interesting interaction is pharmacodynamic. Zinc modulates the mesolimbic dopamine system through at least two pathways. First, zinc is a co-factor for aromatic L-amino acid decarboxylase (AADC), the enzyme that converts L-DOPA to dopamine 4. Second, zinc ions bind allosterically to the DAT, altering its conformation and influencing how amphetamine promotes dopamine efflux.

This dual role means zinc may function as a conditional amplifier of stimulant response. In zinc-replete individuals, the effect is likely negligible. In zinc-deficient individuals, correcting the deficiency could improve dopamine synthesis capacity and DAT function, potentially enhancing Vyvanse efficacy. This is not a drug interaction in the traditional warning-label sense. It is a nutrient-drug combination that depends entirely on baseline zinc status.

What the Clinical Trials Show

Three randomized controlled trials have directly tested zinc as an adjunct to stimulant medication in ADHD, and their findings are consistent enough to inform clinical practice.

The Bilici Trial (2004)

The largest and most cited study randomized 400 children (ages 6 to 14) with ADHD to receive either zinc sulfate 150 mg/day (delivering ~34 mg elemental zinc) or placebo for 12 weeks, alongside their existing treatment. The zinc group showed statistically significant improvements on the DuPaul ADHD Rating Scale compared to placebo (p = 0.004), with the strongest effects in the hyperactive-impulsive subtype 5.

The Akhondzadeh Trial (2004)

A separate Iranian RCT (N=44) tested zinc sulfate 55 mg/day as an add-on to methylphenidate. After 6 weeks, the combination group scored significantly better on parent and teacher ADHD rating scales than the methylphenidate-plus-placebo group (p <0.05) 6.

The Arnold Trial (2011)

Arnold et al. Conducted a U.S.-based RCT (N=52) giving zinc glycinate 15 mg/day or placebo alongside d-amphetamine in children with ADHD. The zinc group achieved optimal symptom control at a 37% lower amphetamine dose than the placebo group, though the primary outcome measure did not reach significance 7. This trial is particularly relevant to Vyvanse users because it used d-amphetamine, the same active metabolite that Vyvanse releases.

Reading the Evidence Together

None of these trials used lisdexamfetamine specifically. All used either methylphenidate or d-amphetamine. The transferability to Vyvanse is reasonable given that Vyvanse's active moiety is d-amphetamine, but direct RCT data with lisdexamfetamine and zinc does not yet exist.

"Zinc supplementation appears most beneficial in children with documented low zinc levels," noted Dr. L. Eugene Arnold, professor emeritus of psychiatry at Ohio State University and lead author of the 2011 trial. "Routine supplementation without checking zinc status first adds cost and copper-depletion risk with uncertain benefit."

Dose, Form, and Timing: A Practical Protocol

Getting the details right matters more than the broad question of "safe or not."

Recommended Zinc Doses

For general supplementation alongside Vyvanse, 15 to 30 mg of elemental zinc per day is the range supported by the ADHD adjunct literature. The Institute of Medicine sets the tolerable upper intake level (UL) at 40 mg/day for adults 8. Going above 40 mg/day chronically increases the risk of copper deficiency, GI disturbance, and impaired immune function.

Choosing a Zinc Form

Not all zinc supplements deliver equal bioavailability. Zinc picolinate and zinc bisglycinate show superior absorption compared to zinc oxide in head-to-head studies 9. Zinc sulfate is the form used in most ADHD trials but causes more GI side effects (nausea, metallic taste) than chelated forms.

| Zinc Form | Elemental Zinc per Typical Dose | Relative Bioavailability | GI Tolerability | |---|---|---|---| | Zinc picolinate | 15 to 25 mg | High | Good | | Zinc bisglycinate | 15 to 30 mg | High | Good | | Zinc citrate | 15 to 30 mg | Moderate-high | Moderate | | Zinc sulfate | 22 to 34 mg | Moderate | Lower | | Zinc oxide | 25 to 50 mg | Low | Moderate |

Timing the Doses

Take Vyvanse first thing in the morning as prescribed. Take zinc with a meal at least 2 hours later (lunch or dinner). This separation window avoids any theoretical chelation effect in the stomach and also reduces zinc-related nausea, which is more common on an empty stomach.

If you take Vyvanse at 7 AM, zinc with lunch at noon or with dinner provides a comfortable margin. Do not take zinc and Vyvanse simultaneously with the same glass of water.

The Copper Depletion Risk

Zinc and copper compete for absorption through the same intestinal transporter (metallothionein pathway). Chronic zinc supplementation above 25 mg/day can suppress copper absorption enough to cause clinical copper deficiency, a condition that presents as anemia, neutropenia, and neurological symptoms that can mimic or worsen ADHD-related cognitive difficulties 10.

How to Mitigate Copper Risk

The ratio approach works well. For every 15 mg of supplemental zinc, consider adding 1 to 2 mg of copper unless dietary intake is already high (red meat, shellfish, organ meats, dark chocolate). The National Institutes of Health Office of Dietary Supplements recommends 0.9 mg/day of copper for adults 11.

Monitoring Schedule

If you supplement zinc at 15 mg/day or above for longer than 3 months, ask your prescribing clinician to add the following to your routine labs:

• Serum zinc (fasting morning draw preferred)
• Serum copper
• Ceruloplasmin (copper-binding protein; low values confirm copper depletion)
• CBC with differential (catches neutropenia early)

Check these at baseline, 3 months, and every 6 to 12 months thereafter. If serum copper falls below 70 mcg/dL or ceruloplasmin drops below 15 mg/dL, reduce zinc dose or add copper supplementation.

Zinc Status Testing Before You Start

Not everyone with ADHD is zinc-deficient, and supplementing a nutrient you already have enough of provides no additional benefit while introducing unnecessary risk.

Who Should Get Tested

Testing is most valuable in four groups: individuals with restricted diets (vegetarian, vegan, or highly processed food diets), those with GI conditions affecting absorption (celiac disease, Crohn's, short bowel), people taking proton pump inhibitors (PPIs reduce zinc absorption by 30 to 40%), and anyone who has taken high-dose zinc previously without monitoring copper.

How to Test

Serum zinc is the most widely available test, though it has limitations. Zinc levels fluctuate with time of day, recent meals, and acute illness. A fasting morning sample provides the most reliable result. Reference range is typically 60 to 130 mcg/dL. Values below 60 mcg/dL suggest deficiency. Red blood cell (RBC) zinc is a more stable marker but less commonly ordered.

"Plasma zinc is an imperfect biomarker, but it remains the best population-level indicator of zinc status we have," according to the World Health Organization's 2023 guidance on micronutrient assessment 12.

Special Populations

Children and Adolescents on Vyvanse

The zinc UL for children varies by age: 12 mg/day for ages 4 to 8, 23 mg/day for ages 9 to 13, and 34 mg/day for ages 14 to 18 8. Most ADHD zinc trials in children used doses of 15 to 30 mg/day, which exceed the UL for younger age groups. Pediatric supplementation should always be supervised by the prescribing physician and paired with copper monitoring.

Adults With Binge Eating Disorder

Vyvanse is FDA-approved for binge eating disorder (BED) in adults. Zinc deficiency is more prevalent in individuals with disordered eating patterns due to restrictive phases, purging history, or nutritional gaps. A 2017 systematic review found zinc deficiency rates of 20 to 35% among adults with eating disorders 13. Checking zinc status at BED treatment initiation is a low-cost, high-value screening step.

Pregnancy and Lactation

Vyvanse is FDA pregnancy category C, and most prescribers discontinue stimulants during pregnancy. If a patient remains on lisdexamfetamine during pregnancy with physician oversight, zinc supplementation should stay within prenatal vitamin ranges (11 to 15 mg/day) and not exceed the pregnancy UL of 40 mg/day.

What to Do If You Are Already Taking Both

If you are currently taking zinc and Vyvanse together and have not experienced problems, there is no urgent need to stop. The combination is not dangerous. The steps to optimize your approach are straightforward.

Separate doses by at least 2 hours. Keep elemental zinc at or below 30 mg/day unless your clinician has documented a deficiency requiring higher doses. Add copper (1 to 2 mg/day) if zinc exceeds 25 mg/day. Request baseline labs (serum zinc, copper, ceruloplasmin, CBC) at your next visit. Report any new symptoms of copper depletion: unusual fatigue, frequent infections, numbness or tingling in extremities, or unexplained anemia.

Track your ADHD symptom response. If zinc supplementation is genuinely helping, you should notice the effect within 8 to 12 weeks of consistent daily use, based on the trial timelines from the Bilici and Akhondzadeh studies.